State-dependent block underlies the tissue specificity of lidocaine action on batrachotoxin-activated cardiac sodium channels.
We have identified two kinetically distinct modes of block, by lidocaine, of cardiac sodium channels, activated by batrachotoxin and incorporated into planar lipid bilayers. Here, we analyze the slow blocking mode which appears as a series of nonconducting events that increase in frequency and duration with increasing lidocaine concentrations. This type of block occurred rarely, if at all, for the skeletal muscle sodium channel subtype. Kinetic analysis showed that a linear open-closed-blocked model is sufficient to account for the major features of our data. Slow block occurs from a long closed state that is a distinguishing characteristic of cardiac channels under these conditions. Slow block showed no significant voltage dependence in the range of -60 to -20 mV for which the detailed kinetic analysis was performed, and was not elicited by application of the permanently charged lidocaine derivative QX-314. By contrast, the fast block, described in the companion paper, results from drug binding to the open state, and is similar for cardiac and skeletal muscle sodium channels. Application of trypsin to the cytoplasmic end of the channel eliminates both the spontaneous, long, gating closures and slow block. Thus, the lidocaine-sensitive closed state of batrachotoxin-activated cardiac sodium channels exhibits a protease susceptibility resembling that of the inactivated state of unmodified sodium channels. It is the slow block caused by lidocaine binding to this closed state that underlies the channel-subtype specificity of lidocaine action in our experiments.
Department of Medical Physiology, University of Calgary, Alberta, Canada.
G W
GW
Zamponi
D D
DD
Doyle
R J
RJ
French
D000818:Animals; D001496:Batrachotoxins / Q000494:pharmacology; D001665:Binding Sites; D002417:Cattle; D004305:Dose-Response Relationship, Drug; D066298:In Vitro Techniques; D015640:Ion Channel Gating; D007700:Kinetics; D008012:Lidocaine / Q000008:administration & dosage / Q000494:pharmacology*; D008051:Lipid Bilayers; D008954:Models, Biological; D009132:Muscles / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism*; D015222:Sodium Channels / Q000187:drug effects* / Q000378:metabolism
D001496:Batrachotoxins; D008051:Lipid Bilayers; D015222:Sodium Channels; D008012:Lidocaine